<DOC>
	<DOCNO>NCT01473901</DOCNO>
	<brief_summary>This clinical study ass dose BKM120 appropriate patient newly diagnose glioblastoma give combination radiotherapy temozolomide .</brief_summary>
	<brief_title>A Phase I Dose Escalation Study BKM120 With Radiation Therapy Temozolomide Patients With Newly Diagnosed Glioblastoma</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Patient ≥ 18 year age day consent signature Patient histologically demonstrate , previously untreated glioblastoma Patient may receive initial treatment GBM follow : For patient enrolled Stage I , must receive least 75 % plan radiotherapy ( 60 Gy ) temozolomide treatment concomitant phase documentation patient 's absolute neutrophil count ( ANC ) ≥ 1.5 x 109/L , platelet count ≥ 100 x 109/L , CTC grade 2 nonhematological toxicity ( except alopecia , nausea , vomit ) concomitant phase treatment within ≥ 4 week ≤ 6 week follow completion temozolomide concomitant phase For patient enrol Stage II , must within ≥ 2 week ≤ 6 week primary GBM resection/biopsy The patient must recover definitive surgical procedure GBM Patient able assess periodic dynamic contrast enhance magnetic resonance imaging ( DCEMRI ) scan Patient Karnofsky performance status &gt; = 60 Patient adequate bone marrow organ function Patient receive previous treatment PI3K and/or mTOR inhibitor GBM preexist neoplasm transform GBM . Patient receive prior antineoplastic therapy BKM , except treatment allow inclusion criterion Patient tumor progression definitive GBM resection/ biopsy , except transformation previous low grade glioma . Patient concurrent malignancy malignancy within 3 year study enrollment ( exception adequately treat , basal squamous cell carcinoma , nonmelanomatous skin cancer curatively resect cervical cancer ) Patient recover grade 1 good adverse event ( except alopecia , nausea , vomit ) relate previous antineoplastic therapy screening procedure initiate , allow inclusion criterion Patient follow baseline mood disorder ( attributable GBM ) judge Investigator Psychiatrist , meet cutoff score ≥ 12 PHQ 9 cutoff ≥ 15 GAD7 mood scale reason attributable GBM ; selects positive response ' 1 , 2 , 3 ' question number 9 regard potential suicidal thought ideation PHQ9 ( independent total score PHQ9 ) Medically documented history active major depressive episode , bipolar disorder ( I II ) , obsessivecompulsive disorder , schizophrenia , history suicidal attempt ideation , homicidal ideation ( immediate risk harm others ) Active severe personality disorder ( define accord DSMIV ) . Note : patient psychotropic treatment ongoing baseline , dose schedule modify within previous 6 week prior start study drug . ≥ CTCAE grade 3 anxiety Patient concurrently use approve investigational antineoplastic agent Patient undergone follow invasive procedure : Major surgical procedure , open biopsy significant traumatic injury &lt; 14 day prior start study drug recover side effect therapy , anticipation need invasive surgical procedure course study , biopsy within 7 day prior start study drug Patient poorly control diabetes mellitus ( HbA1c &gt; 8 % ) Patient currently receive increase chronic treatment corticosteroid another immunosuppressive agent Patient currently receive enzyme induce antiepileptic drug . The patient must discontinue EIAED therapy least two week prior start study drug . Nonenzyme induce antiepileptic medication allow , except list protocol Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>BKM120</keyword>
	<keyword>temozolomide</keyword>
	<keyword>glioblastoma multiforme</keyword>
	<keyword>GBM</keyword>
	<keyword>Newly diagnose</keyword>
</DOC>